Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

被引:62
作者
Heuckmann, Johannes M. [1 ]
Rauh, Daniel [2 ]
Thomas, Roman K. [3 ]
机构
[1] Blackfield, Cologne, Germany
[2] Tech Univ Dortmund, Dortmund, Germany
[3] Univ Cologne, D-50931 Cologne, Germany
关键词
TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; IRREVERSIBLE INHIBITORS; MET AMPLIFICATION; COPY NUMBER; OPEN-LABEL; PHASE-III; GEFITINIB; ERLOTINIB;
D O I
10.1200/JCO.2012.43.1825
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:3417 / 3420
页数:4
相关论文
共 63 条
[1]  
[Anonymous], INT C AM ASS CANC RE
[2]  
[Anonymous], J CLIN ONCOL S
[3]   Activation of tyrosine kinases by mutation of the gatekeeper threonine [J].
Azam, Mohammad ;
Seeliger, Markus A. ;
Gray, Nathanael S. ;
Kuriyan, John ;
Daley, George Q. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (10) :1109-1118
[4]   SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas [J].
Bass, Adam J. ;
Watanabe, Hideo ;
Mermel, Craig H. ;
Yu, Soyoung ;
Perner, Sven ;
Verhaak, Roel G. ;
Kim, So Young ;
Wardwell, Leslie ;
Tamayo, Pablo ;
Gat-Viks, Irit ;
Ramos, Alex H. ;
Woo, Michele S. ;
Weir, Barbara A. ;
Getz, Gad ;
Beroukhim, Rameen ;
O'Kelly, Michael ;
Dutt, Amit ;
Rozenblatt-Rosen, Orit ;
Dziunycz, Piotr ;
Komisarof, Justin ;
Chirieac, Lucian R. ;
LaFargue, Christopher J. ;
Scheble, Veit ;
Wilbertz, Theresia ;
Ma, Changqing ;
Rao, Shilpa ;
Nakagawa, Hiroshi ;
Stairs, Douglas B. ;
Lin, Lin ;
Giordano, Thomas J. ;
Wagner, Patrick ;
Minna, John D. ;
Gazdar, Adi F. ;
Zhu, Chang Qi ;
Brose, Marcia S. ;
Cecconello, Ivan ;
Ribeiro, Ulysses, Jr. ;
Marie, Suely K. ;
Dahl, Olav ;
Shivdasani, Ramesh A. ;
Tsao, Ming-Sound ;
Rubin, Mark A. ;
Wong, Kwok K. ;
Regev, Aviv ;
Hahn, William C. ;
Beer, David G. ;
Rustgi, Anil K. ;
Meyerson, Matthew .
NATURE GENETICS, 2009, 41 (11) :1238-U105
[5]   Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors [J].
Blencke, S ;
Zech, B ;
Engkvist, O ;
Greff, Z ;
Örfi, L ;
Horváth, Z ;
Kéri, G ;
Ullrich, A ;
Daub, H .
CHEMISTRY & BIOLOGY, 2004, 11 (05) :691-701
[6]   Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].
Carter, TA ;
Wodicka, LM ;
Shah, NP ;
Velasco, AM ;
Fabian, MA ;
Treiber, DK ;
Milanov, ZV ;
Atteridge, CE ;
Biggs, WH ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Mehta, SA ;
Patel, HK ;
Pao, W ;
Sawyers, CL ;
Varmus, H ;
Zarrinkar, PP ;
Lockhart, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016
[7]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[8]   Factors predicting response to EGFR tyrosine kinase inhibitors [J].
Engelman, JA ;
Jänne, PA .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) :314-322
[9]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[10]   PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Gale, Christopher-Michael ;
Lifshits, Eugene ;
Gonzales, Andrea J. ;
Shimamura, Takeshi ;
Zhao, Feng ;
Vincent, Patrick W. ;
Naumov, George N. ;
Bradner, James E. ;
Althaus, Irene W. ;
Gandhi, Leena ;
Shapiro, Geoffrey I. ;
Nelson, James M. ;
Heymach, John V. ;
Meyerson, Matthew ;
Wong, Kwok-Kin ;
Janne, Pasi A. .
CANCER RESEARCH, 2007, 67 (24) :11924-11932